GEOMETRY mono-1: capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer
The MET inhibitor capmatinib shrank tumours in two thirds of untreated and four in ten previously treated patients with MET exon 14-skipping lung cancer, leading to the first approval for this driver, while MET-amplified tumours responded only at very high copy number.
Overview
Phase 2 multicohort study of 364 patients with advanced non-small-cell lung cancer with MET exon 14 skipping or MET amplification treated with capmatinib.
In exon 14-skipping disease, objective response was 68 percent in treatment-naive and 41 percent in previously treated patients, with median durations of 12.6 and 9.7 months; in MET-amplified disease, response was 40 percent only with gene copy number of 10 or more. Peripheral oedema and nausea were common.
- Exon 14 skipping: objective response 68 percent (treatment-naive) and 41 percent (previously treated).
- MET amplification: response 40 percent at gene copy number 10 or more, low below that.
MET exon 14 skipping is a standard target in lung cancer, tested by RNA-based methods, with capmatinib or tepotinib as first-line or later options.
- Single-arm; peripheral oedema is frequent and can be dose limiting.
- MET amplification without exon 14 skipping is a weaker target.
Similar pages
not linked directly; found by shared links- Key paperVISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, New England Journal of Medicine.
- TreatmentTepotinib
Shares Capmatinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
- TermMET amplification (bypass resistance)
Shares GEOMETRY mono-1, MET exon 14 and MET-amplified non-small-cell lung cancer.
- TermMET exon 14 skipping mutation
Shares Capmatinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
- TreatmentCrizotinib
Shares GEOMETRY mono-1, Capmatinib, MET exon 14 and MET-amplified non-small-cell lung cancer.